Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Trial Profile

Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Human dermal fibroblasts-SpinalCyte (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Therapeutic Use
  • Acronyms Landmark
  • Sponsors SpinalCyte
  • Most Recent Events

    • 25 Oct 2018 Results of a positive 12 month pain data published in the SpinalCyte Media Release.
    • 17 May 2018 According to a SpinalCyte media release, the company announced that posters from this trial will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018.
    • 12 Apr 2018 According to a SpinalCyte media release, company has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to expand this ongoing study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top